OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
June 03, 2011
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
June 02, 2011
More sophisticated biological expression systems expand the functionality of the traditional systems for protein synthesis.
Academic–industry partnerships are increasingly important in biopharmaceutical innovation.
FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.
May 18, 2011
Filling active ingredients directly into capsules is probably the quickest option for entering clinical trials. This case study compares manual and automated methods of capsule filling.
May 12, 2011
FDA is asking for input on the development of a user-fee program for biosimilar and interchangeable biological product applications.
May 02, 2011
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.
Emerging methods could provide alternative ways of producing inhalable drug particles.
Innovator and generic-drug companies need to adapt to compete in the biosimilars market.